However, despite these links to indicators of more aggressive disease there was no evidence for a difference in overall and cancer-specific survival between those cancers harbouring ETV1 gene alteration and those cancers retaining normal ERG and ETV1 loci (Class N) (HR=1.48, CI=0.87–2.53, P=0.17 and HR=−1.48, CI=0.64–3.46, P=0.39 respectively) (Supplementary Figure 1). This evidence concerns the gene ERG and cancer.